MoonLake Immunotherapeutics (MLTX)
42.79
-0.03
(-0.07%)
USD |
NASDAQ |
May 02, 10:22
MoonLake Immunotherapeutics Cash from Investing (TTM): -25.18M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -25.18M |
September 30, 2023 | -132.15M |
June 30, 2023 | 0.00 |
Date | Value |
---|---|
March 31, 2023 | -12.68M |
December 31, 2022 | -32.34M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-132.15M
Minimum
Sep 2023
--
Maximum
Jun 2023
-40.47M
Average
-25.18M
Median
Dec 2023
Cash from Investing (TTM) Benchmarks
Qiagen NV | -- |
LENZ Therapeutics Inc | -- |
AC Immune SA | 73.11M |
CRISPR Therapeutics AG | 374.65M |
Addex Therapeutics Ltd | -0.0076M |